

**Table S1. Patient Demographics and Clinical Characteristics**

n	100
Females, %	61
Mean age, years (range)	45 (18-74)
Ethnicity, %	
White	61
Black	21
Hispanic	12
Asian	6
Education (highest completed level), %	
High school	15
Bachelor's	74
Master's	11
Mean Disease Duration, years (range)	11.3 (1-51)
Mean EDSS (range)	3.8 (1-6.5)
Mean JCV Ab Index (range)	1.3 (0.1-4.3)
Mean time (months) on natalizumab therapy (n=19)	12.7
Natalizumab naive, n	81
Prior immunosuppressant use, %	3

EDSS, Expanded Disability Status Scale; JCV Ab, John Cunningham virus antibody


**Table S2. Patient-reported Source(s) of Information on Which They Based Their Perception of PML Risk**

Source of Risk Information	n	Risk Perception (%)	Risk Acceptance (%)	Actual Risk (%)
Judged by the concern of my neurologist	63	42.06	16.52	0.014
Biogen patient program	35	27.49	12.14	0.007
Internet	31	12.53	10.39	0.005
Discussed with fellow MS patients	29	33.10	14.13	0.010
Scientific literature	11	0.43	9.28	0.003
Biogen phone call	5	41.00	18.00	0.014
Based on JCV Ab Index level “My index level is 0.7” = 70% risk “My index level is 0.87” = 87% risk	2	78.5	30	0.006

Note: Patients were able to list more than one source of information.

JCV Ab, John Cunningham virus antibody; MS, multiple sclerosis

**Figure S1. Scatterplots of Perceived PML Risk (top) and PML Risk Tolerance (bottom) By Patient Age**



PML, progressive multifocal leukoencephalopathy